CompletedPhase 1NCT05533008

CR845-100303: Study to Assess the Potential of Physical Withdrawal From Intravenous CR845 (Difelikefalin) in Hemodialysis Patients

Studying Complication in hemodialysis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Cara Therapeutics, Inc.
Principal Investigator
Frédérique Menzaghi, PhD
Cara Therapeutics
Intervention
CR845 0.5 mcg/kg(drug)
Enrollment
35 target
Eligibility
18-80 years · All sexes
Timeline
20192020

Study locations (5)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05533008 on ClinicalTrials.gov

Other trials for Complication in hemodialysis

Additional recruiting or active studies for the same condition.

See all trials for Complication in hemodialysis

← Back to all trials